Correction to: Biomark Res (2019) 7:19
https://doi.org/10.1186/s40364-019-0170-2
The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for ‘mitoxantrone, etoposide, cyclophosphamide’.
It should instead be stated that MEC stands for ‘mitoxantrone, etoposide, cytarabine’.
Reference
Zhao J, Song Y, Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomarker Research. 2019;7:19. https://doi.org/10.1186/s40364-019-0170-2.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Zhao, J., Song, Y. & Liu, D. Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomark Res 7, 21 (2019). https://doi.org/10.1186/s40364-019-0172-0
Published:
DOI: https://doi.org/10.1186/s40364-019-0172-0